[Effectiveness and safety of biological therapy with adalimumab].

Abstract

Adalimumab is a human, recombinant antibody, which is effective in patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriasis, arthritis psoriatica, spondylitis ankylopoetica, as well as with Crohn-disease. Adalimumab has got a high affinity binding to tumor necrosis factor (TNF-alfa), this way it inhibits the interactions with TNF and its receptors (soluble and membrane associated). It is well tolerated and safe, it improves the the quality of life. Possible side effects can be decreased by the careful observation and usual control of patients. The authors discuss in detail the publications on adalimumab in the above mentioned diseases.

• Authors: János Fehér, Gabriella Lengyel
• Journal: Orvosi hetilap (Orv Hetil) Vol. 150 Issue 26 Pg. 1215-22 (Jun 28 2009) ISSN: 0030-6002 [Print] Hungary
• Vernacular Title: Az adalimumab biológiai terápia hatékonysága és biztonságossága.
• PMID: 19546078 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antirheumatic Agents
• Tumor Necrosis Factor-alpha
• Adalimumab

Topics

• Adalimumab
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Antibodies, Monoclonal (administration & dosage, adverse effects, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antirheumatic Agents (administration & dosage, adverse effects, therapeutic use)
• Arthritis, Juvenile (drug therapy)
• Arthritis, Psoriatic (drug therapy)
• Arthritis, Rheumatoid (drug therapy)
• Crohn Disease (drug therapy)
• Humans
• Psoriasis (drug therapy)
• Quality of Life
• Spondylitis, Ankylosing (drug therapy)
• Tumor Necrosis Factor-alpha (drug effects, metabolism)